102. Elucidating the genomic landscape of Prostate Adenocarcinoma through whole genome and transcriptome sequencing

Whole Genome and Transcriptome Sequencing (WGTS) testing provides a comprehensive molecular profile of a patient's tumor. Genome sequencing was performed at the New York Genome Center CLIA laboratory, from frozen and FFPE tumor of two cases diagnosed with prostate adenocarcinoma and matched normal blood DNA. RNA sequencing of the two separate tumors was also performed using NYGC proprietary analysis pipeline. Results of the first specimen showed two biallelic inactivating CDK12 alterations, focal tandem duplications across entire genome and a high rate of DNA fusions likely due to DNA mismatch repair error.

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Marilena Melas, Heather Geiger, Sowmya T. Srinivasa, Saurav Guha, Vanessa Felice, Lena Fielding, Amanda Thomas-Wilson, Ashley Wilson, Theresa MacDonald, Ryan Smith, Jyothi Manohar, Michelle Primiano, Olivier Elemento, Ravi Sharaf, Kazimierz O. Wrzeszczyns Source Type: research